A new clinical trial led by biotech firm MindMed suggests that one carefully measured dose of LSD could significantly reduce symptoms of generalized anxiety disorder (GAD). Unlike many other treatments, the findings stand out because the trial required no psychotherapy support.
Conducted with 198 adults aged 18 to 74, the study tested four different LSD dosages against a placebo under strict clinical supervision. Notably, within just 24 hours, patients who received higher doses — 100 or 200 micrograms — began reporting major relief from anxiety. By week four, their improvements outpaced those of participants who received smaller amounts or a placebo.
By the twelfth week, nearly 65% of patients in the 100 microgram group still showed significant progress, and almost half had entered full remission. Moreover, symptoms of depression also decreased within this group, reinforcing researchers’ belief that 100 micrograms may be the optimal dosage for future testing.
Safety remained a priority throughout. While side effects such as nausea, hallucinations, and headaches did occur, researchers confirmed there were no cases of self-harm or suicidal behavior. The FDA has now granted the treatment “breakthrough therapy” status, potentially accelerating its approval process. In addition, MindMed has already begun a larger Phase 3 trial expected to conclude in 2026.
Experts view these results as a potential game-changer. Psychiatry has seen little innovation for GAD since 2007, yet psychedelics like LSD could mark a turning point. For a broader context on how innovation reshapes music and wellness communities, revisit our feature on AI in music. To learn more about breakthrough therapy designations, see the FDA’s guidance here.
H/T: EDMTunes
